Cellectis S.A. (CLLS) Form 6-K — Aug 6, 2026

$CLLSForm 6-KFiled Aug 6, 2026, 4:35 PM ET0001171843-26-005324Original filing

Cellectis reported Q2 2026 results with a net loss of $21.8 million ($0.22 per share) and a first-half net loss of $39.6 million ($0.39 per share), while cash, cash equivalents, restricted cash and fixed-term deposits stood at $169 million as of June 30, 2026, funding operations into Q4 2027. On the pipeline, lasme-cel received FDA RMAT designation in June 2026 for relapsed or refractory CD22-positive B-ALL, and full Phase 1 BALLI-01 data showed a 100% overall response rate in the seven-patient target Phase 2 population, with the pivotal Phase 2 first interim analysis expected in Q4 2026.

Key figures

Eps: -$0.39 H1 2026 net loss per share; -$0.22 Q2 2026
Revenue: $14.5 million H1 2026 consolidated revenues and other income ($6.9 million in Q2 2026)
Net Income: -$39.6 million H1 2026 net loss attributable to shareholders; -$21.8 million Q2 2026 net loss
Revenue Yoy: -52% (stated $15.8 million decrease for H1 revenues and other income vs $30.2 million in H1 2025)
Total Assets: $267.4 million as of June 30, 2026
Cash Position: $169 million (cash, cash equivalents, restricted cash and fixed-term deposits as of June 30, 2026)
Cash runway: into Q4 2027
Restricted cash: $2.3 million
Cash dec 31 2025: $211 million
Fixed term deposits: $131.1 million
Rd expenses h1 2026: $52.2 million (vs $45.0 million H1 2025)
Sga expenses h1 2026: $11.3 million (vs $9.8 million H1 2025)
Operating loss h1 2026: $48.7 million (vs $23.8 million H1 2025)
Adjusted net loss h1 2026: $35.6 million ($0.35 per share)
Adjusted net loss q2 2026: $19.5 million ($0.19 per share)
Net financial gain h1 2026: $9.2 million (vs $18.1 million net financial loss H1 2025)
Eti cel optimal dose cohort: 88% ORR, 63% CR (n=8)
Weighted avg shares q2 2026: 100647451
H1 2025 revenue other income: $30.2 million
Q2 2025 revenue other income: $18.2 million
Current financial liabilities: $7.5 million
Pivotal phase2 interim analysis: Q4 2026
Shareholders equity jun 30 2026: $41.1 million (vs $75.9 million at Dec 31, 2025)
Non current financial liabilities: $66.2 million
Eib warrant fair value gain h1 2026: $8.7 million
Lasme cel orr target phase2 population: 100% (7/7); CR/CRi 57%

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.